Advanced search
Publication Cover
Cell Cycle Volume 15, 2016 - Issue 24
Submit an article Journal homepage
1,948
Views
40
CrossRef citations to date
0
Altmetric
Report

STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer

Elisabet CuyàsProgram Against Cancer Therapeutic Resistance (ProCURE), Metabolism and Cancer Group, Catalan Institute of Oncology, Girona, Catalonia, Spain;Molecular Oncology Group, Girona Biomedical Research Institute (IDIBGI), Girona, Spain
,
Almudena Pérez-SánchezMolecular and Cell Biology Institute, Miguel Hernández University, Elche, Spain
,
Vicente MicolMolecular and Cell Biology Institute, Miguel Hernández University, Elche, Spain
,
Javier A. MenendezProgram Against Cancer Therapeutic Resistance (ProCURE), Metabolism and Cancer Group, Catalan Institute of Oncology, Girona, Catalonia, Spain;Molecular Oncology Group, Girona Biomedical Research Institute (IDIBGI), Girona, SpainCorrespondence[email protected] [email protected]
&
Joaquim Bosch-BarreraMolecular Oncology Group, Girona Biomedical Research Institute (IDIBGI), Girona, Spain;Deparment of Medical Oncology, Catalan Institute of Oncology, Girona, Catalonia, Spain;Department of Medical Sciences, Medical School, University of Girona, Girona, Spain
Pages 3413-3418 | Received 19 Sep 2016, Accepted 30 Sep 2016, Published online: 28 Nov 2016

Citations (40)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Hui Chen, Qiang Zhang, Yu Zhang, Bin Jia, Bin Zhang & Changli Wang. (2018) Afatinib reverses ceritinib resistance (CR) in ALK/ROS1-positive non-small-cell lung cancer cell (NSCLC) via suppression of NRG1 pathway. OncoTargets and Therapy 11, pages 8201-8209.
Read now
Daniel B. Costa. (2017) Resistance to ALK inhibitors: Pharmacokinetics, mutations or bypass signaling?. Cell Cycle 16:1, pages 19-20.
Read now

Articles from other publishers (38)

Qi Zhang, Chenying Yang, Xingsu Gao, Ju Dong & Caiyun Zhong. (2023) Phytochemicals in regulating PD ‐1/ PD‐L1 and immune checkpoint blockade therapy . Phytotherapy Research.
Crossref
Shuangyu Liu, Lingyu Li & Dongmei Ren. (2023) Anti-Cancer Potential of Phytochemicals: The Regulation of the Epithelial-Mesenchymal Transition. Molecules 28:13, pages 5069.
Crossref
Sunanda Singh, Hector J. Gomez, Shreya Thakkar, Samara P. Singh & Ashutosh S. Parihar. (2023) Overcoming Acquired Drug Resistance to Cancer Therapies through Targeted STAT3 Inhibition. International Journal of Molecular Sciences 24:5, pages 4722.
Crossref
Sara Verdura, Jose Antonio Encinar, Eduard Teixidor, Antonio Segura-Carretero, Vicente Micol, Elisabet Cuyàs, Joaquim Bosch-Barrera & Javier A. Menendez. (2022) Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors. Cancers 14:24, pages 6101.
Crossref
Kunjing Liu, Qi Sun, Qi Liu, Huayao Li, Wenfeng Zhang & Changgang Sun. (2022) Focus on immune checkpoint PD-1/PD-L1 pathway: New advances of polyphenol phytochemicals in tumor immunotherapy. Biomedicine & Pharmacotherapy 154, pages 113618.
Crossref
Sara Verdura, José Antonio Encinar, Salvador Fernández-Arroyo, Jorge Joven, Elisabet Cuyàs, Joaquim Bosch-Barrera & Javier A. Menendez. (2022) Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells. International Journal of Molecular Sciences 23:17, pages 9986.
Crossref
Songtao Dong, Xiangnan Guo, Fei Han, Zhonggui He & Yongjun Wang. (2022) Emerging role of natural products in cancer immunotherapy. Acta Pharmaceutica Sinica B 12:3, pages 1163-1185.
Crossref
Yaming Ding, Zhang Zhen, Muhammad Azhar Nisar, Farman Ali, Riaz Ud Din, Muhammad Khan, Tafail Akbar Mughal, Gulzar Alam, Linlin Liu & Muhammad Zubair Saleem. (2022) Sesquiterpene Lactones Attenuate Paclitaxel Resistance Via Inhibiting MALAT1/STAT3/ FUT4 Axis and P-Glycoprotein Transporters in Lung Cancer Cells. Frontiers in Pharmacology 13.
Crossref
Tomas Koltai & Larry Fliegel. (2022) Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions. Journal of Evidence-Based Integrative Medicine 27, pages 2515690X2110688.
Crossref
Nour Y.S. Yassin, Sameh F. AbouZid, Asmaa M. El-Kalaawy, Tarek M. Ali, Mazen M. Almehmadi & Osama M. Ahmed. (2022) Silybum marianum total extract, silymarin and silibinin abate hepatocarcinogenesis and hepatocellular carcinoma growth via modulation of the HGF/c-Met, Wnt/β-catenin, and PI3K/Akt/mTOR signaling pathways. Biomedicine & Pharmacotherapy 145, pages 112409.
Crossref
Shrestha Nensi & John Ashton. (2021) ALK-Positive Non-Small Cell Lung Cancer; Potential Combination Drug Treatments. Current Cancer Drug Targets 21:9, pages 737-748.
Crossref
Nour Y. S. Yassin, Sameh F. AbouZid, Asmaa M. El-Kalaawy, Tarek M. Ali, Basem H. Elesawy & Osama M. Ahmed. (2021) Tackling of Renal Carcinogenesis in Wistar Rats by Silybum marianum Total Extract, Silymarin, and Silibinin via Modulation of Oxidative Stress, Apoptosis, Nrf2, PPARγ, NF-κB, and PI3K/Akt Signaling Pathways. Oxidative Medicine and Cellular Longevity 2021, pages 1-19.
Crossref
Juwon Lee, Youngjin Han, Wenyu Wang, HyunA Jo, Heeyeon Kim, Soochi Kim, Kyung-Min Yang, Seong-Jin Kim, Danny N. Dhanasekaran & Yong Sang Song. (2021) Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy. Biomolecules 11:8, pages 1107.
Crossref
Sara Verdura, Elisabet Cuyàs, Verónica Ruiz-Torres, Vicente Micol, Jorge Joven, Joaquim Bosch-Barrera & Javier A. Menendez. (2021) Lung Cancer Management with Silibinin: A Historical and Translational Perspective. Pharmaceuticals 14:6, pages 559.
Crossref
Md. Abdul Aziz, Md. Shahid Sarwar, Tahmina Akter, Md. Sahab Uddin, Song Xun, Yu Zhu, Mohammad Safiqul Islam & Zhang Hongjie. (2021) Polyphenolic molecules targeting STAT3 pathway for the treatment of cancer. Life Sciences 268, pages 118999.
Crossref
Fateme Chavoshy, Behzad Sharif Makhmal Zadeh, Ali Mohammad Tamaddon & Mohammad Houssin Anbardar. (2020) Delivery and Anti-Psoriatic Effect of Silibinin-Loaded Polymeric Micelles: An Experimental Study in the Psoriatic Skin Model. Current Drug Delivery 17:9, pages 787-798.
Crossref
Mahdi Mashhadi Akbar Boojar, Massoud Mashhadi Akbar Boojar & Sepide Golmohammad. (2020) Overview of Silibinin anti-tumor effects. Journal of Herbal Medicine 23, pages 100375.
Crossref
Leïla Sarah Sellam, Roberta Zappasodi, Fayçal Chettibi, Djamel Djennaoui, Nadia Yahi-Ait Mesbah, Zine-Charaf Amir-Tidadini, Chafia Touil-Boukoffa, Wahiba Ouahioune, Taha Merghoub & Mehdi Bourouba. (2020) Silibinin down-regulates PD-L1 expression in nasopharyngeal carcinoma by interfering with tumor cell glycolytic metabolism. Archives of Biochemistry and Biophysics 690, pages 108479.
Crossref
Carmen Tse, Ashleigh Warner, Rufaik Farook & James G Cronin. (2020) Phytochemical Targeting of STAT3 Orchestrated Lipid Metabolism in Therapy-Resistant Cancers. Biomolecules 10:8, pages 1118.
Crossref
Joaquim Bosch-Barrera, Begoña Martin-Castillo, Maria Buxó, Joan Brunet, José Antonio Encinar & Javier A. Menendez. (2020) Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patients. Journal of Clinical Medicine 9:6, pages 1770.
Crossref
Yanrong Li, Kai Wang, Na Song, Kezuo Hou, Xiaofang Che, Yang Zhou, Yunpeng Liu & Jingdong Zhang. (2019) Activation of IGF-1R pathway and NPM-ALK G1269A mutation confer resistance to crizotinib treatment in NPM-ALK positive lymphoma. Investigational New Drugs 38:3, pages 599-609.
Crossref
József Dudás, Andrea Ladányi, Julia Ingruber, Teresa Bernadette Steinbichler & Herbert Riechelmann. (2020) Epithelial to Mesenchymal Transition: A Mechanism that Fuels Cancer Radio/Chemoresistance. Cells 9:2, pages 428.
Crossref
Dominique Reed, Komal Raina & Rajesh Agarwal. 2020. Natural Products for Cancer Chemoprevention. Natural Products for Cancer Chemoprevention 161 208 .
Elisabet Cuyàs, Sara Verdura, Vicente Micol, Jorge Joven, Joaquim Bosch-Barrera, José Antonio Encinar & Javier A. Menendez. (2019) Revisiting silibinin as a novobiocin-like Hsp90 C-terminal inhibitor: Computational modeling and experimental validation. Food and Chemical Toxicology 132, pages 110645.
Crossref
Chao-Yue Sun, Juan Nie, Jie-Peng Huang, Guang-Juan Zheng & Bing Feng. (2019) Targeting STAT3 inhibition to reverse cisplatin resistance. Biomedicine & Pharmacotherapy 117, pages 109135.
Crossref
Linlin Chang, Yan Hu, Yingying Fu, Tianyi Zhou, Jun You, Jiamin Du, Lin Zheng, Ji Cao, Meidan Ying, Xiaoyang Dai, Dan Su, Qiaojun He, Hong Zhu & Bo Yang. (2019) Targeting slug-mediated non-canonical activation of c-Met to overcome chemo-resistance in metastatic ovarian cancer cells. Acta Pharmaceutica Sinica B 9:3, pages 484-495.
Crossref
Yi Lai, Merve Kacal, Maraam Kanony, Iga Stukan, Kenbugul Jatta, Lorand Kis, Erik Norberg, Helin Vakifahmetoglu-Norberg, Rolf Lewensohn, Per Hydbring & Simon Ekman. (2019) miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC. Biochemical and Biophysical Research Communications 511:2, pages 260-265.
Crossref
Almudena Pérez-Sánchez, Elisabet Cuyàs, Verónica Ruiz-Torres, Luz Agulló-Chazarra, Sara Verdura, Isabel González-Álvarez, Marival Bermejo, Jorge Joven, Vicente Micol, Joaquim Bosch-Barrera & Javier Menendez. (2019) Intestinal Permeability Study of Clinically Relevant Formulations of Silibinin in Caco-2 Cell Monolayers. International Journal of Molecular Sciences 20:7, pages 1606.
Crossref
Chia-Huei Lee, Ji-Rui Yang, Chih-Yu Chen, Ming-Hsien Tsai, Pin-Feng Hung, Shin-Jih Chen, Shang-Lun Chiang, Han Chang & Pinpin Lin. (2019) Novel STAT3 Inhibitor LDOC1 Targets Phospho-JAK2 for Degradation by Interacting with LNX1 and Regulates the Aggressiveness of Lung Cancer. Cancers 11:1, pages 63.
Crossref
Zhengzheng Shi, Qing Zhou, Shuhong Gao, Wenzhi Li, Xin Li, Zhiming Liu, Pengpeng Jin & Jie Jiang. (2019) Silibinin inhibits endometrial carcinoma via blocking pathways of STAT3 activation and SREBP1-mediated lipid accumulation. Life Sciences 217, pages 70-80.
Crossref
Qi Yang, Wenyu Chen, Yufeng Xu, Xiaodong Lv, Ming Zhang & Hao Jiang. (2018) Polyphyllin I modulates MALAT1/STAT3 signaling to induce apoptosis in gefitinib-resistant non-small cell lung cancer. Toxicology and Applied Pharmacology 356, pages 1-7.
Crossref
Jie Gao, Zhongjun Shao, Min Yan, Ting Fu, Lei Zhang & Yongping Yan. (2018) Targeted regulationof STAT3 by miR-29a in mediating Taxol resistance of nasopharyngeal carcinoma cell line CNE-1. Cancer Biomarkers 22:4, pages 641-648.
Crossref
Dong-Hoon Won, Lee-Han Kim, Boonsil Jang, In-Hyoung Yang, Hye-Jeong Kwon, Bohwan Jin, Seung Hyun Oh, Ju-Hee Kang, Seong-Doo Hong, Ji-Ae Shin & Sung-Dae Cho. (2018) In vitro and in vivo anti-cancer activity of silymarin on oral cancer. Tumor Biology 40:5, pages 101042831877617.
Crossref
Arpit Dheeraj, Dhanir Tailor, Surya P. Singh & Rana P. Singh. 2018. Role of Nutraceuticals in Chemoresistance to Cancer. Role of Nutraceuticals in Chemoresistance to Cancer 199 220 .
Kalliopi TsakiriVassiliki KotoulaSotirios LakisJudith MüllerFlorentia FostiraMattheos BobosProdromos HytiroglouGeorge Fountzilas. (2017) Crizotinib Failure in a TPM4-ALK –Rearranged Inflammatory Myofibroblastic Tumor With an Emerging ALK Kinase Domain Mutation . JCO Precision Oncology:1, pages 1-7.
Crossref
Hai Zou, Xing-Xing Zhu, Guo-Bing Zhang, Yuan Ma, Yi Wu & Dong-Sheng Huang. (2017) Silibinin: an old drug for hematological disorders. Oncotarget 8:51, pages 89307-89314.
Crossref
Joaquim Bosch-Barrera, Bernardo Queralt & Javier A. Menendez. (2017) Targeting STAT3 with silibinin to improve cancer therapeutics. Cancer Treatment Reviews 58, pages 61-69.
Crossref
Fedra Luciano-Mateo, Anna Hernández-Aguilera, Noemi Cabre, Jordi Camps, Salvador Fernández-Arroyo, Jose Lopez-Miranda, Javier Menendez & Jorge Joven. (2017) Nutrients in Energy and One-Carbon Metabolism: Learning from Metformin Users. Nutrients 9:2, pages 121.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.